How to Evaluate Site SOPs During Clinical Trial Feasibility Assessments

Introduction: The Role of SOPs in Trial Readiness

Standard Operating Procedures (SOPs) are essential components of a clinical trial site’s quality system. They provide documented instructions for critical trial activities such as informed consent, investigational product (IP) handling, adverse event (AE) reporting, source data documentation, and data entry. For sponsors and CROs conducting feasibility assessments, evaluating a site’s SOP portfolio offers key insights into trial readiness, GCP compliance, and operational maturity.

During regulatory inspections, deficiencies in SOPs are frequently cited findings. These include outdated procedures, missing SOPs for core functions, or failure to follow written procedures. As a result, sponsors must thoroughly assess SOP quality, completeness, and relevance during site qualification and feasibility planning.

This article outlines a structured approach for evaluating clinical site SOPs during feasibility reviews, including checklists, document control practices, alignment with protocol needs, and inspection readiness indicators.

1. Importance of SOP Review During Feasibility

While infrastructure and staffing evaluations assess physical and human readiness, SOP review examines whether processes are standardized, traceable, and capable of consistent protocol execution. Without reliable SOPs, even experienced staff may introduce variability or overlook regulatory obligations.

Evaluating SOPs helps determine:

• If the site has written procedures for essential clinical functions
• If SOPs are up-to-date, approved, and version controlled
• If staff have been trained and documented on applicable SOPs
• If site SOPs align with sponsor expectations and protocol-specific activities

A site may have sufficient infrastructure and an experienced PI, but if there is no SOP for AE/SAE reporting or IP accountability, the trial is at risk of non-compliance.

2. Essential SOPs to Verify During Feasibility

Sponsors should request and review a list of active SOPs, particularly those relevant to clinical trial execution. The following SOPs are considered minimum requirements for most interventional studies:

Additional SOPs may be required depending on protocol complexity (e.g., genetic sample handling, radiology imaging transfer, central lab management).

3. SOP Quality Review Criteria

Beyond the presence of SOPs, sponsors should review the quality and structure of the documents. Each SOP should meet the following criteria:

• Clearly titled and numbered per a standardized SOP index
• Includes version number, effective date, and revision history
• Approved by site management and quality representatives
• Written in a clear, step-by-step format with defined roles and responsibilities
• Reflects current regulatory expectations (FDA, EMA, ICH)
• Last review date within 24 months or earlier if protocol demands updates

Example SOP Header Review:

4. Staff Training and SOP Compliance Documentation

SOPs are only useful if site staff are trained on them. Sponsors should request:

• Staff training logs indicating completion of relevant SOPs
• Sign-in sheets or electronic training records with dates
• Staff acknowledgment of role-specific SOPs
• Retraining plans for SOP revisions

Feasibility teams should verify that the PI, study coordinator, pharmacist, and lab staff have been trained on core SOPs applicable to their duties. For instance, a sub-investigator managing patient consent must be trained on the ICF process SOP.

5. SOP Alignment with Protocol and Sponsor Requirements

Some SOPs may be too generic to support protocol-specific requirements. Sponsors should identify gaps such as:

• Protocol requires SAE reporting within 24 hours, but site SOP states 72 hours
• Sponsor uses eConsent, but site SOP only covers paper-based processes
• Protocol requires weekly IP temperature uploads, but SOP outlines monthly review

In such cases, sponsors can request a protocol-specific work instruction or temporary process deviation with training logs. Sites with flexible SOP structures and rapid document revision workflows are generally better prepared for fast-paced studies.

6. SOPs and Regulatory Inspection Readiness

During FDA or EMA inspections, SOPs are routinely requested by auditors to evaluate GCP compliance. Common inspection findings include:

• No SOPs available at site during the visit
• SOPs signed by unauthorized personnel
• SOPs contradict sponsor instructions or protocol requirements
• Training logs incomplete or missing
• Staff unaware of content or location of SOPs

Sites should maintain SOPs in a central regulatory binder or electronic SOP system that is accessible to all staff. Version control, approval history, and archival practices must be documented and compliant with 21 CFR Part 11 or Annex 11 where applicable.

7. Best Practices for Sponsors and CROs

• Request SOP index and list during initial feasibility outreach
• Pre-review SOPs during pre-study visits (PSV) or remotely for e-feasibility
• Document findings using standardized SOP review templates
• Collaborate with site to align SOPs with protocol-specific needs
• Include SOP review as a line item in site qualification reports and TMF

Conclusion

Evaluating a site’s SOPs is an indispensable part of clinical trial feasibility and site qualification. SOPs are not only a reflection of operational quality but also form the basis of regulatory compliance and protocol adherence. Sponsors must move beyond check-the-box SOP lists and actively verify that procedures are documented, current, aligned with the trial, and embedded in staff training. A well-prepared site with robust SOP governance is far more likely to deliver quality data, meet timelines, and withstand regulatory scrutiny.